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model that explains both the origin and spo-
radic nature of cancer argues that cancer cells
are a chance result of events that cause genomic
and epigenetic variability. The prevailing view is that
these events are mutations that affect chromosome segre-
gation or stability. However, genomic and epigenetic
variability is also triggered by cell fusion, which is often
caused by viruses. Yet, cells fused by viruses are consid-
ered harmless because they die. We provide evidence
that a primate virus uses both viral and exosomal pro-
A
 
teins involved in cell fusion to produce transformed prolif-
erating human cells. Although normal cells indeed fail to
proliferate after fusion, expression of an oncogene or a
mutated tumor suppressor p53 in just one of the fusion
partners is sufficient to produce heterogeneous progeny.
We also show that this virus can produce viable oncogen-
ically transformed cells by fusing cells that are otherwise
destined to die. Therefore, we argue that viruses can con-
tribute to carcinogenesis by fusing cells.
 
Introduction
 
Two models have been provided to explain the sporadic nature of
cancer. One posits that cancer is a result of accumulated random
mutations and the other that it is a consequence of events that
cause genomic instability. The second model was formulated a
century ago (Hansemann, 1890; for review see Boveri, 1929) by
postulating that cancer results from aberrant mitoses that produce
aneuploid cells, in which chromosomes are abnormal in their
number or structure. Although most of these abnormalities are le-
thal, this model argues that some of their combinations produce a
cancerous cell. This model has regained interest because of the
accumulating evidence that chromosomes of tumor cells are
nearly invariantly abnormal in their number, structure, or both,
although whether aneuploidy is a cause or consequence of onco-
genic transformation is still being debated (for review see Dues-
berg et al., 2004; Rajagopalan and Lengauer, 2004).
Mutations that affect cell cycle progression, chromo-
somes, or the mitotic machinery are often considered to be the
main, if not exclusive, causes of aneuploidy (Rajagopalan and
Lengauer, 2004). However, another well-documented cause is
cell fusion, which produces a wide range of chromosomal aber-
rations, including chromosomal loss, chromosome disjunctions,
and translocations (Ringertz and Savage, 1976; for review see
Duelli and Lazebnik, 2003). Although mutations and cell fu-
sion can both lead to aneuploidy, progeny of cell fusion may
be more viable and diverse. Fusion combines centrosomes of
the fusion partners, which increases the likelihood of multiple
mitoses that often produce aneuploid cells. Fusion also imme-
diately doubles the number of chromosomes, thereby decreas-
ing the chances that the loss of a chromosome will kill the cell.
Furthermore, fusion of cells that are in different phases of the
cell cycle often results in premature chromosome condensa-
tion, which leads to massive chromosome fragmentation,
with the fragments distributed among the daughter cells
(Ringertz and Savage, 1976). Finally, fusion between pheno-
typically distinct cells produces hybrids that not only are genet-
ically diverse but also have unique sets of properties resulting
from an apparently random rearrangement of epigenetic and
other regulatory networks of the fusion partners (Ringertz
and Savage, 1976).
Given that cell fusion causes aneuploidy and that aneu-
ploidy may cause cancer (Rajagopalan and Lengauer, 2004), it
follows that cell fusion has the potential to produce cancerous
cells. This hypothesis was also proposed a century ago (Klebs,
1887; Aichel, 1911), based on the observation that both cell hy-
brids and cancer cells are aneuploid and on a conjecture, which
proved to be correct, that both fusion and oncogenic transfor-
mation cause an unusual reassortment of epigenetic regulatory
mechanisms. More recent studies have provided a substantial
body of evidence in support of this model, including the ob-
servation that the metastatic potential of tumor cells can be
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increased by fusing them with macrophages or dendritic cells
(for review see Duelli and Lazebnik, 2003).
In the body, fused cells originate from physiological and
illicit cell fusion. Physiological fusion is required to produce
the zygote and several types of multinuclear somatic cells, such
as myotubes and osteoclasts (for review see Chen and Olson,
2005). Mechanisms of physiological cell fusion are only begin-
ning to emerge but already prove to be complex (for review see
Chen and Olson, 2005). Importantly, with the exception of the
zygote and, perhaps, hybrids produced from stem cells (O’Malley
and Scott, 2004), cells produced by physiological cell fusion
are terminally differentiated and do not proliferate.
Illicit cell fusion is caused by a variety of agents, includ-
ing viruses and chemicals, or by abnormal expression of cellu-
lar proteins. Cell fusion caused by such agents as polyethylene
glycol (PEG) or inactivated Sendai virus has been used routinely
as an experimental tool. Despite the evidence that experimental
cell fusion can produce abnormal cells, such as hybridomas or
radiation hybrids, the potential pathological consequences of
illicit cell fusion are poorly understood.
Viruses are of particular interest as pathological fusogens
because they are ubiquitous, diverse, and amplifiable; can per-
sist in cells inconspicuously; and have been implicated in car-
cinogenesis. Cell fusion is a side effect of viral proteins, such
as retroviral Env, that mediate fusion between the virus and the
plasma membrane.
If intact viruses can produce aneuploid hybrids in vivo,
as inactivated Sendai virus does in vitro, then viruses should
be considered causative agents of aneuploidy, even if they are
otherwise harmless. However, a current view is that cells
fused by intact viruses either die or do not proliferate (Zhivo-
tovsky and Kroemer, 2004). This view has been established
sufficiently to use virus-induced cell fusion to kill cancer cells
as a therapeutic approach (Peng et al., 2002). The cytotoxic and
cytostatic effects of virus-induced fusion are attributable to a
response either to fusion by itself or to the resulting aneu-
ploidy, as well as the response to the virus (Zhivotovsky and
Kroemer, 2004).
We report that a primate virus that shares properties with
exosomes can produce transformed proliferating hybrids from
human cells. Although normal cells indeed failed to proliferate
after fusion with this virus, they did produce heterogeneous
proliferating progeny if one of the fusion partners expressed
an oncogene or a mutant of the tumor suppressor p53. We
also demonstrate that this virus produced viable oncogenically
transformed cells by fusing cells destined to die. Overall, we
argue that cell fusion can be one of the processes that links
viruses and carcinogenesis.
 
Results
 
This study resulted from using cell fusion as a tool to investigate
how expression of the oncogenes Myc or adenoviral E1A sensi-
tizes cells to chemotherapy-induced apoptosis (Duelli and La-
zebnik, 2000). In one of the experiments, we needed to monitor
cells produced by fusion of normal and E1A-expressing cells.
We used PEG to fuse normal human fibroblasts that expressed a
puromycin-resistance gene (I0
 
P
 
 cells) with fibroblasts that ex-
pressed both a hygromycin-resistance gene and E1A (IE
 
H
 
 cells).
As expected, I0
 
P
 
 cells were killed by hygromycin and IE
 
H
 
 cells
by puromycin (Fig. 1 A). Therefore, we expected only hybrids
produced by PEG to proliferate in the presence of both drugs. To
our surprise, we found that the number of proliferating cells did
not depend on the PEG treatment (Fig. 1 B). One possible expla-
nation was that cells fused spontaneously. We were intrigued by
this possibility because of the link between fusion and carcino-
genesis, the numerous reports that cancer cell lines are inexplica-
bly fusogenic (for review see Duelli and Lazebnik, 2003), our
finding that transformed cells acquire resistance to anticancer
agents through fusion to normal cells (Duelli and Lazebnik,
2000), and the observation that cells recovered from individual
colonies vary widely in their properties (unpublished data).
Figure 1. Spontaneous fusion produces proliferating hybrids. (A) IMR90
cells (I0) resistant to puromycin (I0P) or I0 cells transformed with E1A and
resistant to hygromycin (IEH) were cultured as indicated and stained with
crystal violet to visualize the cells. (B) Co-culture of I0P and IEH cells results
in cells resistant to both drugs. Cells were plated together, treated with
PEG or left untreated, cultured for 20 d, and visualized as in A. (C and D)
IEH cells fuse to each other but not to themselves. I0P and IEH cells were
dyed and cultured as indicated for 16 h and visualized by fluorescence
microscopy. Heterokaryons (indicated by arrows in C and scored in D)
contained both green and blue dyes and at least one green and one blue
nucleus. (E) Tissue culture medium from IEH cells induces cell fusion. Tissue
culture medium conditioned by either I0P or IEH cells for 16 h was tested in
the fusion assay (see Materials and methods). All experiments were per-
formed at least three times. The data in D and E are from three independent
experiments, and the error bars indicate SD.
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Cells fuse spontaneously
 
To test whether cells fused, we used an assay in which fusion
partners were stained with vital fluorescent dyes of different
colors, and the fused cells were identified as heterokaryons that
contained both dyes in the cytoplasm and at least two differ-
ently colored nuclei (Duelli and Lazebnik, 2000; see also Mate-
rials and methods). We stained IE
 
H
 
 and I0
 
P
 
 cells, cultured them
together for 16 h, and identified heterokaryons by fluorescence
microscopy (Fig. 1 C, left). IE
 
H
 
 and I0
 
P
 
 cells indeed fused with
each other (Fig. 1, C and D). We noticed that fused cells were
mostly dikaryons, which are more likely to produce proliferating
progeny than cells containing more nuclei (Ringertz and Savage,
1976); only rarely contained several nuclei; and were never
found as syncytia, which are indicative of viral infections. Re-
markably, neither IE
 
H
 
 nor I0
 
P
 
 cells fused to their own kind (Fig.
1 D), which suggested either that these cells collaborated to fuse,
as happens in myogenesis, or that one of the lines made a fuso-
gen that was unable to fuse the cells that produced it.
 
Cells release a fusogen associated with 
exosomes
 
Consistent with the second possibility, tissue culture medium
conditioned by IE
 
H
 
 cells fused I0
 
P
 
 cells and several other cell
lines that we tested, whereas the medium conditioned by I0
 
P
 
cells did not (Fig. 1 E and not depicted). Enriching the fu-
sogenic activity by filtration and sequential centrifugation
yielded a preparation we called P70 (Fig. 2 A) and indicated
that the fusogen was 100–200 nm in size. Because trypsin treat-
ment of the P70 abolished the fusogenicity (Fig. 2 B), we iden-
tified the digested peptides by mass spectrometry. About half
of the reliably identified proteins were reported as components
of exosomes (Table S1, available at http://www.jcb.org/cgi/
content/full/jcb.200507069/DC1).
Exosomes are vesicles of characteristic shape, protein
composition, and size that are released by many cells, in partic-
ular tumor cell lines (Couzin, 2005). These vesicles have been
used in clinical trials to induce T cell–mediated tumor rejection
(for review see Chaput et al., 2004), although the function of
exosomes in vivo, if any, is unclear. Exosomes may serve as
shuttles by delivering proteins and lipids to cells and carry pro-
teins implicated in cell fusion, such as CD9 and -81 (Hemler,
2003; Fevrier and Raposo, 2004). To verify that the fusogenic
activity is associated with exosomes, we analyzed other param-
eters that define these vesicles.
The electron microscopy of P70 from IE
 
H
 
 cells revealed
uniform particles (Fig. 2 C) whose cuplike shape and size was
consistent with that described for exosomes (Thery et al.,
2001). Fractionation of P70 from both I0 and IE
 
H
 
 cells by flota-
tion in a sucrose gradient provided particles with a density
(1.18 g/ml), appearance, and CD81 content (Fig. 2 D) consis-
tent with that of exosomes (Thery et al., 2001). The fusogenic
activity from IE
 
H
 
 cells co-migrated with exosomes in the gradi-
ents (Fig. 2 E). However, exosome preparations from I0 cells
fused none of the cell lines that we tested at any concentration
used (Fig. 2 F and not depicted), indicating that either fuso-
genic activity is not associated with exosomes or the exosomes
from I0
 
P
 
 and IE
 
H
 
 cells are different.
 
Fusogenic exosomes contain viral proteins
 
A possible difference was suggested by the Trojan exosome hy-
pothesis, which states that retroviruses, many of which are fuso-
genic, can be released in exosomes. Using this mechanism, the
virus may expand its host range by using cellular proteins incor-
porated in its membrane to facilitate fusion and to avoid im-
mune surveillance (Gould et al., 2003). Therefore, we repeated
the mass spectrometry analysis, this time using total lysates of
purified exosomes (Fig. 3 A). Major polypeptides recovered
from the fractions with fusogenic activity (fraction 7; Fig. 3,
A and C) were encoded by the Mason-Pfizer monkey virus
(MPMV; Table S2, available at http://www.jcb.org/cgi/content/
full/jcb.200507069/DC1; for review see Fine and Schochetman,
1978), suggesting that exosomes carried this virus.
MPMV is the prototype D type retrovirus with a host
range largely restricted to primates. The virus was originally
isolated from a rhesus monkey breast carcinoma and then de-
tected in humans (Bohannon et al., 1991; Ford et al., 1992) and
in many human cell lines (Robert-Guroff et al., 1996). MPMV
can cause simian acquired immunodeficiency syndrome but
has no identified pathogenic effect in humans or in cultured
Figure 2. Fusion activity is associated with exosomes. (A) Fusogenic ac-
tivity is enriched by sequential centrifugation. Conditioned medium from
IEH cells (S0) was sequentially centrifuged at 500, 16,000, 70,000, and
110,000 g. A pellet from each centrifugation was reconstituted and used
in the fusion assay with I0 cells. (B) P70 obtained as in A was treated with
trypsin or buffer (see Materials and methods), and the fusogenicity of the
resulting preparations was determined as in A. (C) Electron micrograph of
P70 from IEH cells. (D and E) P70 was fractionated by floating in a sucrose
gradient, and the fractions were analyzed for CD81 (D) and in the fusion
assay with I0 cells (E). (F) Exosomes from I0 cells are not fusogenic. Indi-
cated concentrations of exosomes from either I0 or IEH cells were tested in
the fusion assay with I0 cells. The experiments in A, B, and F were per-
formed at least three times. The data in D and E are from one of three exper-
iments, and the data in A and B are from the same experiment. The error
bars in A, B, and F indicate SDs.
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cells. Ectopic expression of the MPMV Env is sufficient to in-
duce cell fusion (Song and Hunter, 2003), which indicates that
the fusogenicity of IE
 
H
 
 cells could be associated with this virus.
Because our observation suggested that proliferating hybrids
could be produced by a virus, we verified that the fusion that
we observed was indeed caused by MPMV.
Several observations supported this possibility. The genome
of IE
 
H
 
 but not that of I0 cells contained MPMV sequences (un-
published data). The P70 from IE
 
H
 
 but not from I0 cells had re-
verse transcriptase activity (Fig. 3 B, inset). Also, I0 cells became
fusogenic (Fig. S1, A and C, available at http://www.jcb.org/cgi/
content/full/jcb.200507069/DC1) and acquired expression of
MPMV p27
 
CA
 
 after incubation with P70 from either IE
 
H
 
 or
CMMT, which is the prototypical cell line that produces MPMV
(for review see Fine and Schochetman, 1978; Fig. S1 B and not
depicted). Immunoblotting confirmed that P70 of IE
 
H
 
 cells con-
tained the exosomal proteins CD9, CD81, and major histocom-
patibility complex class I (MHCI; Thery et al., 1999) and the
MPMV proteins gp20 Env and the capsid p27
 
CA
 
 Gag (Fig. 4 A).
Nearly all particles in P70 from IE
 
H
 
 cells contained the MPMV
capsid protein p27
 
CA
 
 (Fig. 4 B) in its mature form (Fig. 4 A), indi-
cating that nearly all observed vesicles contained MPMV.
Nearly all vesicles also had CD81 on their surface (Fig. 4 B),
consistent with the possibility that the virus was carried by exo-
somes. We tested this possibility by capturing exosomes with an
antibody to CD81 and assessing whether the viral proteins segre-
gated with this exosomal marker. All Env and most p27
 
CA
 
 indeed
segregated with CD81, as did another tetraspanin, CD63 (Fig. 4 C;
Pelchen-Matthews et al., 2003). Considering our observations,
we concluded that MPMV was released as an exosome-like
particle and will refer to this form of the virus as MPMV
 
E
 
.
Figure 3. Fusogenicity is associated with an exosome-like virus. (A and B)
Exosomes were fractionated by sedimentation in a velocity gradient (see
Materials and methods), and aliquots of the fractions were analyzed in the
fusion assay with I0 cells (A) or reverse transcriptase activity (B). The insets
in A show an electron micrograph of fraction 7 and the content of CD81 in
the fractions analyzed by dot blotting. The inset in B compares the reverse
transcriptase activity in P70 from I0 and IEH cells. (C) The fractions obtained
in A were analyzed by electrophoresis and the indicated polypeptides by
mass spectrometry (Table S2). The data in A and in the inset in B are from
three independent experiments, and the data in B are the mean of two inde-
pendent experiments. The error bars indicate SD.
Figure 4. Fusogenic exosomes are associated with MPMV. (A) MPMV Env,
Gag, and exosomal CD9, CD81, and MHCI were detected by immunoblot-
ting in P70 (see Materials and methods). (B) CD81 is detected on the surface
and p27Ca Gag of MPMV inside of exosomes by immuno-EM (see Materials
and methods). The inset is an enlargement of the particle indicated by the ar-
row. (C) MPMV Env and p27 capsid are associated with exosomal markers
CD81 and -63. P70 preparation was incubated with or without biotinylated
anti-human CD81 antibody and fractionated in a capture assay using mag-
netic streptavidin microbeads (see Materials and methods). The unbound
fraction (FT), the final wash, and the bound fraction (eluate) were analyzed
by immunoblotting. Antibodies to CD63 and -81 were used together for con-
venience because both identify distinct polypeptides. The experiments in A
and B were done multiple times and the experiment in C twice.
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Antibodies to exosomal proteins 
interfere with fusion
 
MPMV
 
E
 
 contained two sets of proteins implicated in fusion, the
MPMV Env and the cellular tetraspanins CD81 and -9, which
modulate fusion by a poorly understood mechanism. To test
whether tetraspanins are involved in cell fusion induced by
MPMV
 
E
 
, we used the observation that antibodies to CD9 and -81
prevent fusion of mouse gametes and myoblasts (Hemler, 2003).
We incubated aliquots of MPMV
 
E
 
 with antibodies to CD9, CD81,
the capsid p27
 
CA
 
, or the MPMV Env gp20/22. To exclude unspe-
cific effects of antibodies, we used total mouse IgG and an anti-
body to MHCI, an abundant exosome surface protein (Clayton et
al., 2001) that has not been linked to fusion (Fig. 4 C and Fig. 5 A).
Antibodies to Env, CD9, and CD81, but not to the capsid protein
p27
 
CA
 
, did bind MPMV
 
E
 
 (Fig. 5 A), confirming that Env and the
tetraspanins were on the surface of MPMV
 
E
 
 and that the envelope
of MPMV
 
E
 
 was intact. After washing away the unbound antibod-
ies, we tested whether the treated MPMV
 
E
 
 still fused I0 cells.
Antibodies to CD9 or -81 blocked fusion, whereas the
control antibodies had no effect (Fig. 5 B). Treating MPMV
 
E
 
with the antibody to CD81 also prevented fusion of HepG2
cells (Fig. 5 B), which express no detectable CD81 (Fig. 5 C;
Charrin et al., 2001), indicating that the effect of this antibody
is associated with its binding to CD81 located on MPMV
 
E
 
rather than on cells. Considering our observations and the re-
ported function of tetraspanins, we concluded that exosomal
proteins participate, directly or indirectly, in cell fusion in-
duced by MPMV
 
E
 
. How these proteins affect fusion remains to
be determined. The role of MPMV Env also remains unclear,
as the ability of the antibody that we used to block membrane
fusion or infection in any experimental system is unknown.
 
MPMV
 
E
 
 infection is not required for fusion
 
Cells can be fused by proteins of the viral particles, which does
not require infection, or by viral proteins that are expressed in the
infected cells. Several observations indicated that cell fusion in-
duced by MPMV
 
E
 
 did not require infection. MPMV
 
E
 
 had to be
continuously present in the medium to induce cell fusion (Fig.
6 A), which implies that fusion was directly caused by the added
viral particles. Cell fusion was detectable within hours (Fig. 6 A),
as opposed to the days required to express MPMV proteins (Fine
et al., 1979), which is consistent with the finding that fused cells
have no detectable MPMV proteins (Fig. S2 A, available at
http://www.jcb.org/cgi/content/full/jcb.200507069/DC1). Azi-
dothymidine, a reverse transcriptase inhibitor, prevented infec-
tion but not fusion (Fig. S2 B). Finally, the efficiencies of cell
fusion and productive infection were unrelated (Fig. 6 B), con-
firming that fusion of the virus to the cells and fusion of cells in-
duced by viruses or viruslike particles can be different processes
(Schmid et al., 2000) and suggesting that hybrids produced by vi-
ruses may have no trace of the virus that created them, meaning
that their viral etiology would be impossible to determine.
 
Oncogenes abolish a proliferation block 
caused by fusion
 
Because our observations contrasted with the view that cells
fused by active viruses do not proliferate, we investigated what is
required to make hybrids proliferate. None of the normal pri-
mary cell lines that we tested, which included human fibroblasts
I0, HSF43, SF68, BJ, WI38, and Detroit 551; human umbilical
vein endothelial cells; and renal proximal epithelial tubule cells,
produced colonies or mononuclear cells after fusion by MPMV
 
E
 
(Fig. 7 A, left, and not depicted). Therefore, we concluded that
these cells not only failed to proliferate but did not undergo even
a single cell division after fusion. The cells were dikaryons, with
occasional polykaryons, and remained attached for at least 20 d
and appeared healthy (Fig. S2 C). Therefore, cell fusion was cy-
tostatic but not cytotoxic to normal cells. Hence, we concluded
that fusion of normal differentiated cells by MPMV
 
E
 
 is unlikely
to result in proliferating progeny.
Figure 5. Antibodies to tetraspanins CD9 and -81 inhibit
fusion by MPMVE. (A) Aliquots of MPMVE were incubated
with indicated antibodies, washed, and analyzed by immu-
noblotting (see Materials and methods). (B) Exosomes were
treated with indicated antibodies and tested in the fusion as-
say with I0 or HepG2 cells, which express no CD81 (C). The
experiments were done three times with I0 cells, except that
total mouse IgG was used as a control only in two of these
experiments, and the experiments with HepG2 cells were
done twice. ND, not done. The error bars indicate SD. (C)
CD81 is transferred to HepG2 cells by MPMVE. HepG2 cells
cultured for 22 h without (left) or with (right) MPMVE from IEH
cells were probed with an antibody to CD81 (red). The nuclei
were visualized with Hoechst 33342 (blue).
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Our initial observation (Fig. 1) suggested that expres-
sion of E1A may allow proliferation of fused cells. Indeed,
we found that fusing normal and E1A-expressing fibroblasts
yielded proliferating hybrids (Fig. 7 A, middle). However,
cells transduced with E1A had to be passaged eight or more
times to produce viable hybrids, perhaps to select cells that are
less prone to apoptosis. Ectopic expression of c-Myc also al-
lowed proliferation, although the efficiency was lower (un-
published data). These observations raised the possibility that
fusion can produce malignant cells from cells that have dereg-
ulated cell cycles.
 
Inactivating tumor suppressor p53 
abolishes a proliferation block caused 
by fusion
 
Cell cycle arrest induced by fusion was reminiscent of arrest
caused by incomplete cytokinesis, which can be inactivated by
dominant-negative mutants of p53 (Margolis et al., 2003), one
of which, p53-R172H (p53-R175H in humans), causes meta-
static aneuploid tumors in mice (Hingorani et al., 2005). There-
fore, we tested whether expression of p53-R175H would allow
cells fused by MPMV
 
E
 
 to proliferate.
Indeed, fusion of normal Detroit 511 cells (D0
 
P
 
) with
cells that were transduced with p53-R175H (Dp53R175H
 
H
 
)
produced proliferating hybrids (Fig. 7 A, right). The morphol-
ogy and the rate of proliferation of hybrids produced with either
gene varied widely (Fig. 7 B and not depicted), but p53-R175H
was more efficient in producing proliferating hybrids than
E1A, and the hybrids were different. Instead of forming well-
defined colonies, as did hybrids expressing E1A, the p53-
R175H hybrids spread throughout the plate (Fig. 7 A). Given
that expression of neither E1A nor p53-R175H affected the rate
or extent of cell fusion, we concluded that proliferation of cells
produced by fusion is controlled by a mechanism that can be
deregulated by mutation of p53 and that a single mutation in
one of the fusion partners is sufficient to result in diverse pro-
liferating hybrids.
 
Fusion produces transformed hybrids 
from cells destined to die
 
Cell fusion can add to cell diversity by combining distinct
properties of the fusion partners. For example, genes that are
insufficient to transform on their own may be brought together
by cell fusion to result in a transforming combination. To test
whether MPMV
 
E
 
 has this effect, we used the observation that
expressing E1A together with oncogenic Ras results in trans-
formed cells that grow in soft agar, whereas expressing E1A
alone induces apoptosis and expressing Ras senescence (Seger
et al., 2002). Indeed, Detroit 511 cells that were freshly trans-
duced with E1A (DE
 
H
 
) or that expressed Ha-Ras (DRas
 
P
 
) alone
failed to form colonies in soft agar (Fig. 8). In contrast, hybrids
of DE
 
H
 
 and DRas
 
P
 
 produced by MPMV
 
E
 
 grew at least as effi-
ciently in soft agar as did the cells cotransduced with E1A and
Ha-Ras (Fig. 5). Hybrids recovered from soft agar also grew
efficiently in tissue culture, whereas no parental cells could be
recovered, implying that neighboring cells, even if they are
otherwise destined to die, could produce transformed prolifer-
ating progeny if fused by a virus.
Figure 6. Cells are fused by MPMVE particles.
(A) MPMVE must be continuously present in the
medium to induce fusion. MPMVE was added
to I0 cells, and the fused cells were scored at
the indicated times (top, curve indicated with
filled circles). Alternatively, MPMVE was
added to one of the fusion partners for the in-
dicated time, after which the cells were
washed three times to remove unbound MP-
MVE, and the second fusion partner was
added and the fused cells scored 16 h later
(bottom, curve indicated with filled triangles).
(B) The infection and fusion efficiencies of
MPMVE do not correlate. Various amounts of MPMVE were added to the fusion assay with I0 cells, which were then incubated for 16 h to score fused
cells or for 4 d to score for reverse transcriptase (RT) activity in tissue culture medium. The data are from three independent experiments, and the error
bars indicate SD.
Figure 7. Expression of E1A or suppression of p53 is sufficient for prolif-
eration of hybrids induced by MPMVE. (A) Detroit 551 cells resistant to
puromycin (D0P), hygromycin (D0H), transduced with E1A and resistant to
hygromycin (DEH), or transduced with p53 R175H and resistant to hygro-
mycin (Dp53R175HH) were cultured for 16 h in combinations as indicated
with or without MPMVE and then for an additional 20 d in fresh medium
containing hygromycin and puromycin. The cells were then visualized by
staining with crystal violet. (B) Cell colonies from various fields of the bottom
right plate in A. Note the diversity in cell morphology among the fields.
The data are from one out of three experiments, all of which produced
similar results. Bars, 200 m.
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Discussion
 
Overall, we found that a primate virus can produce diverse ab-
normal proliferating cells by cell fusion and that proliferation
of these cells is favored by expression of oncogenes or by a
mutated tumor suppressor, p53. Whether proliferating hybrids
are produced by viruses in vivo
 
,
 
 and whether these hybrids can
evolve into cancerous cells, remains to be determined.
At least two sets of observations suggest that viruses pro-
duce not only moribund syncytia but also proliferating hybrids.
For example, human cancer cells grafted into rodents produce
tumors that partially or completely consist of host-human hy-
brids and host tumor cells that appear to be derived by sponta-
neous fusion, which is a term used to describe fusion with an
unknown cause (Goldenberg et al., 1974; Pathak et al., 1997;
Mortensen et al., 2004). Interestingly, mouse cancer cell lines
passaged in mice can increase or acquire their metastatic poten-
tial by spontaneous fusion to host cells (for review see Duelli
and Lazebnik, 2003).
Why these tumor cells are fusogenic is unclear. Our ob-
servations suggest an explanation: fusion is caused by viruses
or viruslike particles. Indeed, not only are retroviruses ubiqui-
tous in mice, but some viruses were specifically associated
with xenografts and the resulting tumors (Bowen et al., 1983;
Ristevski et al., 1999). We found that 7 out of the 20 human tu-
mor cell lines that we tested released a particulate fusogen,
which is consistent with the possibility that these tumor cell
lines released fusogenic viruses (unpublished data).
Another example of cell fusion that remains unexplained
is the production of hybrids between bone marrow stem cells
and differentiated somatic cells (O’Malley and Scott, 2004; for
review see Vignery, 2005). Bone marrow stem cells can give
rise not only to somatic differentiated cells but also to gastric
cancer by a mechanism that is unclear (Houghton et al., 2004).
One possibility that was raised (Marx, 2004) but not tested is
that oncogenic transformation in this case was also caused by
fusion. Again, viruses may be the fusogen, a possibility that
would also explain the puzzlingly low frequency of stem-cell
hybrids (10
 

 
5
 
; O’Malley and Scott, 2004).
An intriguing question is why hybrids of stem cells are
capable of proliferating. Our observations suggest that the an-
swer may be in the plastic cell cycle regulation in stem cells,
which makes them similar to embryonic or to partially trans-
formed cells (Attar and Scadden, 2004). Therefore, the ability
to survive and proliferate after fusion, rather than to fuse, may
be a particular characteristic of stem cells that underlies fusion-
mediated transdifferentiation, and perhaps cancer, and allows
one to detect these hybrids in vivo. Given that fusing somatic
cells is being considered as a therapeutic approach (Cowan et
al., 2005), it is of practical interest to know for certain that this
fusion does not produce malignant progeny.
Whether hybrids observed in animal models occur in
humans is unclear, although the reports of premature chro-
mosome condensation (Kovacs, 1985) and hybrids between
transplanted and host cells (Chakraborty et al., 2004) are con-
sistent with this possibility. There is little doubt, however, that
virus-induced cell fusion in people is common, as syncytia are
a feature of many viral infections, from the respiratory syncytial
virus to human immunodeficiency virus.
 
What kind of viruses can produce 
proliferating hybrids?
 
Our finding that a virus can produce proliferating hybrids was
fortuitous. MPMV is neither cytotoxic nor cytostatic in human
cells and in our system primarily produced dikaryons, which
are more likely to result in proliferating hybrids than cells with
more nuclei. It is unlikely that these characteristics are unique
for this virus.
One group are the viruses that, like MPMV, are consid-
ered harmless and therefore are studied much less intensely
than obvious pathogens. For example, human T cell lympho-
tropic virus type 1 (HTLV-1) is harmless to most of its carriers,
and its association with cancer was uncovered only by epide-
miological studies. However, cytotoxic viruses could also
produce hybrids by fusion with noninfectious viral particles,
which are often more abundant than infectious particles, or if
infection is restricted by host factors. In either case, the hybrids
may have no traces of the virus, implying that the viral etiology
of virus-induced hybrids could be difficult to determine. Because
oncogenes can allow proliferation of fused cells, fusogenic
viruses carrying such oncogenes (e.g., 
 
myc
 
) may not only fuse
cells but also allow the hybrids to proliferate. Retroviruses may
achieve a similar effect by insertional mutagenesis.
The ability to form dikaryons, which are more likely to
have proliferating progeny, may depend not only on the virus
but also on how and from what kind of cell it is released. For
example, if a virus is released as a part of exosomes, it may
carry cellular proteins, such as tetraspanin CD9 and -81, that
Figure 8. Fusion produces transformed hybrids from cells destined to die.
(A) Detroit 551 cells freshly transduced with E1A and resistant to hygromy-
cin (DEH), transduced with Ha-Ras and resistant to puromycin (DRasP), or
cotransduced with both E1A and Ha-Ras and resistant to both antibiotics
(DE1ARasHP) were cultured for 16 h alone or in combination, as indicated,
with or without MPMVE. The cells were then cultured for 7 d without added
virus in medium containing hygromycin (DEH), puromycin (DRasP), or both
(DE1ARasHP and the co-cultured DEH and DRasP treated with MPMVE).
The cells were then collected, plated into soft agar at equal cell densities
as indicated, cultured for 20 d, and visualized by crystal violet. (B) Cell
colonies in the corresponding bottom panels in A. The experiment was
done four times with similar results. Bars, 100 m.
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facilitate fusion of cells. Tetraspanins may also be acquired by
the viruses that are released from tetraspanin microdomains of
the plasma membrane (Hemler, 2003; Martin et al., 2005).
Endogenous retroviruses (ERVs), whose sequences com-
prise at least 8% of the human genome (Griffiths, 2001), are
also candidates as pathogenic fusogens. At least three Env pro-
teins of human ERV are fusogenic, two of which, Syncytin 1
and 2, are normally expressed only in the placenta, where they
mediate fusion required for formation of the syncytiotropho-
blast. The third protein, Env(P)b, whose physiological function
is unknown, is expressed ubiquitously (Blaise et al., 2005).
Interestingly, expression of ERVs is regulated by a variety of
factors, including DNA damage, mitogens, and hormones
(Taruscio and Mantovani, 2004). Overall, the possibility that
viruses produce proliferating hybrids should at least be consid-
ered in developing cancer treatments that use fusogenic viruses
to kill cells or as vectors for gene therapy.
Are exosomes misidentified viruses?
Because exosomes and some viruses are so similar, at least
some particles reported as exosomes may be misidentified vi-
ruses. This possibility has practical implications because exo-
somes are used in cancer therapy (for review see Chaput et al.,
2004). Indeed, early reported compositions of exosomes did in-
clude retroviral proteins (Thery et al., 1999, 2001). As we
found, identifying vesicles as exosomes or viruses by mass
spectrometry depends on the protocol used. Defining parame-
ters such as size, shape, and density in sucrose gradients are
also conspicuously similar (for review see Fine and Schochet-
man, 1978; Thery et al., 1999). The morphology of MPMV
(Smith et al., 1978), a pleomorphic virus, is difficult to distin-
guish from that of exosomes.
Cell fusion as a link between viruses and 
carcinogenesis
A current view is that retroviruses transform cells either by in-
tegrating into the cellular genome, thereby affecting normal
gene expression or modifying cellular genes, or by introducing
oncogenes in the genome of infected cells. However, the trans-
formation induced by viruses is unlikely to be limited by these
mechanisms, as indicated by the recent findings that the Env
proteins of Jaagsiekte virus and enzootic nasal tumor viruses
are causative agents of infectious cancer in animals (Wootton
et al., 2005).
Whether retroviruses cause human cancer is a subject of
discussion. The claim that they do is based on epidemiological
data (for review see Mant et al., 2004), whereas the claim that
they do not is based on the argument that viruses fail the require-
ments imposed by Koch’s postulates (Duesberg, 1987; Blaho
and Aaronson, 1999; Talbot and Crawford, 2004). These postu-
lates, as applied to cancer, argue that a candidate virus must be
present in cancer but not in healthy cells, must be isolated from
the cancer cells, must cause oncogenic transformation if intro-
duced into normal cells, and must be present in these cells once
they are transformed. Indeed, if these standards apply, the proof
that viruses are etiological agents of human cancer falls short
(for review see Mant et al., 2004). For example, only 1% of the
people infected with HTLV-1 develop cancer with no apparent
correlation between carcinogenesis and the virus integration sites
(Hanai et al., 2004), whereas another small fraction of the carriers
develop a disease unrelated to cancer.
However, Koch’s postulates are valid only if the causal
relationship between viruses and oncogenic transformation is
as direct as that between viruses and infectious diseases,
which is an assumption that is consistent with the current
view of viral oncogenesis. If the causal relationship between
viruses and oncogenic transformation includes events with
random outcomes in respect to carcinogenesis, such as cell
fusion and abnormal mitoses, and the virus may even be ab-
sent in the cells it produced, then the cause–effect relation-
ship between viruses and cancer is intrinsically stochastic
(Fig. 9), which would mean that Koch’s postulates do not ap-
ply. Therefore, the observed correlations between viral infec-
tions and human cancer may be more than coincidental, even
though because of its random nature it may be impossible, in
principle, to establish a mechanistic link by analyzing only
cancer cells.
Irrespective to the origin of cancer cells, cell fusion has
the potential to promote diversity of transformed cells, as our
results and previous studies have demonstrated. In this case,
the frequency with which proliferating hybrids are produced
would be even higher because at least one of the fusion part-
ners has a deregulated cell cycle and, perhaps, greater sur-
vival capabilities.
Figure 9. Cell fusion as a link between viruses and carcinogenesis. Potential
implications of our findings to carcinogenesis could be summarized by the
following speculative model. Although illicit cell fusion induced by viruses
may be a frequent and common event, it usually has no consequences for
carcinogenesis because, as a rule, the resulting cells either die or do not
proliferate. However, if the cells have a deregulated cell cycle and if the
virus tends to produce dikaryons rather than syncytia, the fused cells may
proliferate. The majority of these cells, however, die within a few cell di-
visions because of chromosomal aberrations associated with abnormal
mitoses or other, yet unrecognized, consequences of cell fusion. How-
ever, the few cells that survive are abnormal in that they have a deregu-
lated cell cycle, lack normal response to this deregulation, are aneuploid,
and have epigenetic regulation that is an unpredictable result of the
merger between fusion partners. A combination of these properties in a
minute fraction of the fused cells may be sufficient to make them cancerous.
Considering that a single cell can give rise to a cancer, the frequency with
which cell fusion produces such cells does not need to be high to have
pathological consequences.
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Overall, the evidence presented in this study suggests a
mechanistic link between viral infections and the genetic and
epigenetic instability model of carcinogenesis. Whether this
link contributes to carcinogenesis or cancer progression remains
to be determined.
Materials and methods
Cell lines and tissue culture
Normal human diploid embryonic lung fibroblast cell line IMR90 and nor-
mal human diploid skin fibroblast cell lines Detroit 551, HSF43, and Hs68,
as well as transformed monkey cell lines COS-1 and CMMT cell lines were
obtained from American Type Culture Collection and cultured in 90% DME
and 10% FBS and in the absence of antibiotics. Normal human diploid skin
fibroblast cell line BJ and normal human diploid lung fibroblasts WI-38
were cultured in 90% MEM and 10% FBS and nonessential amino acids.
Renal proximal tubule cells were obtained from Cambrex and cultured in
REGM renal epithelial cell medium from the same manufacturer. Normal hu-
man umbilical vein endothelial cells were obtained from Cambrex and were
maintained in Ham’s F12K medium with 2 mM L-glutamine. All cells were
routinely monitored for mycoplasma contamination using the Mycoplasma
detection kit 2 (American Type Culture Collection).
Gene transduction
Retroviral vectors pMarxIVpuro, pMarxIVhygro, pBABEpuro, and pWZL-
hygro or the vectors containing 12S E1A, Ha-Ras, or p53 dominant-neg-
ative mutant were transfected (all constructs were gifts from G. Hannon,
the Hannon Laboratory, Cold Spring Harbor, NY) into the packaging cell
line Phoenix-ampho (a gift from G. Nolan, Stanford University, Stanford,
CA) using fugene (Roche). 96 h later, culture supernatant was filtered
through a 0.45-m filter, supplemented with 8 g/ml polybrene, and
added to freshly plated 70% confluent recipient cells that were centri-
fuged for 1 h at 500 g, replated after reaching confluency, and selected
with appropriate antibiotics.
Antibodies
Mouse mAbs to human CD9, -63, and -81 were purchased from BD Bio-
sciences and IgG of murine serum from Sigma-Aldrich. The biotinylated
antibody to human CD81 was obtained from Ancell. The HC-10 antibody
to human MHCI was a gift from H. Ploegh (Harvard Medical School,
Cambridge, MA). The mAb F2-1 to Pr86, gp20, and gp22 of MPMV
(Sommerfelt et al., 2003) was a gift from J. Yee and N. Pedersen (Califor-
nia National Primate Research Center, Davis, CA). Goat antiserum to
MPMV p27Ca was provided by D. Ott (Science Applications International
Corporation–Frederick and National Cancer Institute–Frederick, Frederick,
MD). Secondary antibodies used for immunofluorescence were goat anti–
mouse IgG and donkey anti–goat labeled with AlexaFluor 594 (Invitrogen)
and for immunoblotting anti-mouse HRP (GE Healthcare) and anti-goat
HRP (Santa Cruz Biotechnology, Inc.).
Fusion assay
All fusion experiments were performed in media with no antibiotics, fungi-
cides, or fungistats, as such compounds influence the mode or efficiency
of fusion. Assays were performed in Falcon Multiwell 24-well plates (BD
Biosciences) as described previously (Duelli and Lazebnik, 2000). In brief,
3  104 to 4  104 of one fusion partner that had been dyed with Cell-
Tracker Green CMFDA (5-chloromethylfluorescein diacetate; Invitrogen)
were plated with the same number of cells of another fusion partner that
had been dyed with CellTracker Blue CMAC (7-amino-4-chloromethylcou-
marin; Invitrogen) and cultured for 12–16 h, unless otherwise indicated, in
500–1,000 l of medium or in medium supplemented with a tested fuso-
gen, as indicated in the figure legends. The fusion rate was assessed by
immunofluorescence by measuring the fraction of green cells that became
part of a heterokaryon. At least 600 cells were counted for each data
point, and each experiment was performed at least twice, unless other-
wise indicated.
Exosome purification
To prepare exosomes, cells were grown in DME that was supplemented
with the serum replacement TM-235 (MP Biomedicals), Nutridoma HU
(Roche; for mass spectrometry/mass spectrometry [MS/MS] analyses), or
FBS, as indicated in the figure legends. FBS was clarified of particulate
matter by centrifugation at 110,000 g for 2 h, and the medium was fil-
tered through 0.2-m filters after FBS was added. The resulting medium
contained no exosome-like, or other, particles detectable by EM. The me-
dium was used to culture 1–20 15-cm culture dishes containing I0 or IEH
cells to near confluency. The conditioned tissue culture medium was col-
lected and clarified by centrifugation at 500 g and filtered through Acrodisc
0.2-m HT Tuffryn filters (Pall Corporation), and the filtrate was subjected
to successive centrifugation at 12,000, 70,000, and 110,00 g. The
70,000-g pellet (P70) was resuspended in PBS at 1% of the initial volume
of tissue culture medium and used for further applications immediately or
stored at 70C.
Exosomes were purified by flotation in sucrose gradients using a
published protocol (Thery et al., 1999). In brief, 100 l of freshly ob-
tained P70 was applied under a 12-ml 0.25–2 M gradient of sucrose in
PBS. The resulting samples were centrifuged at 100,000 g for 24 h and
collected as 1-ml fractions. The fractions were diluted with PBS, their
content was pelleted at 70,000 g, and the pellets were assessed for fu-
sogenicity. Purification on iodixanol gradients, which provided a better
yield of fusogenic activity, was performed by overlaying 100 l of con-
centrated P70 onto a 10-ml PBS gradient of 0.6–30% OptiPrep (Axis-
Shield PoC). To test for fusogenicity, the fractions were directly added to
1 ml of medium to achieve a final concentration of no more than 3%
OptiPrep.
Capture assay
The assay was performed using MACS streptavidin microbeads (Miltenyi
Biotec) according to the manufacturer’s instructions. 50 l of P70 prepara-
tion was incubated for 30 min with 0.5 g of the biotinylated anti-human
CD81 antibody, complemented with 20 l of MACS streptavidin micro-
beads, and incubated for 10 min. The suspension was then applied to
magnetized  columns. The unbound material was collected, and the
bound material was washed four times with PBS supplemented with 2%
FBS and released into SDS sample buffer.
Mass spectrometry
Exosomes purified on iodixanol gradients were precipitated in TCA,
washed in acetone, and lysed in hot SDS buffer. The lysates were fraction-
ated by electrophoresis on precast NuPage 4–12% BisTris gels (Invitrogen),
and the proteins were visualized with zinc staining (Bio-Rad Laboratories)
and excised and processed for identification by mass spectrometry. Spectra
resulting from matrix-assisted laser desorption ionization–time of flight/time
of flight mass spectrometry were analyzed using an ABI4700 (Applied Bio-
systems) and the MASCOT search engine (Matrix Science, Inc.).
Analysis of peptides released after treatment of the P70 with trypsin
(Roche) for 12 h was performed after removing particulate matter from the
digest by centrifugation. Liquid chromatography-MS/MS was performed
using 75-m  5-cm picofrit columns (New Objective) coupled directly
to an LCQdeca (Thermo Savant). Spectra resulting from liquid chroma-
tography-MS/MS were analyzed using the SONARS software package
(Genomic Solutions).
Plating assay to visualize proliferating hybrids
Cell lines, as indicated in the figure legends, were plated at equal ratios
in 10-cm dishes at 60% confluency and treated with P70 or medium
alone. 24 h after the treatment, the medium was replaced with that con-
taining puromycin and hygromycin and cultured until the cell colonies
became visible (for 1 wk or longer), and it was replaced with fresh me-
dium every 5 d. To obtain the hybrids by PEG, we cultured I0P and IEH
cells as a mixture and fused them as described previously (Duelli and
Lazebnik, 2000).
Effect of antibodies to CD9 and -81 on fusion
Mouse IgG and the antibodies to CD9 and -81 were diluted to 5 ng/ml.
The HC-10 ascites to MHCI and goat sera were diluted at 1:100, and F2-1
tissue culture supernatant to Env was diluted at 1:10 in medium containing
clarified 10% FBS. All antibodies were then clarified by centrifugation.
Aliquots of P70 were incubated with these antibodies for 2 h at RT and
washed three times by centrifugation at 16,000 g with PBS. No antibod-
ies were detected by immunoblotting in the supernatant of the third wash.
The final pellets were resuspended in PBS to use in the fusion assay or in
SDS sample buffer to analyze by immunoblotting. The amounts of the anti-
body–MPMVE complexes were normalized using MPMV reverse tran-
scriptase activity.
Reverse transcriptase assay
The colorimetric reverse transcriptase assay (Roche) was performed ac-
cording to the manufacturer’s recommendations.
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EM
Purified exosomes were directly adsorbed to butvar-coated grids followed
by negative staining/embedding in 1% aqueous uranyl acetate in 1%
methyl cellulose (Raposo et al., 1996). Micrographs were taken using a
transmission electron microscope (H7000T; Hitachi).
Routine transmission EM of purified exosomes was done by fixation
in suspension with 2% PFA and 0.2% glutaraldehyde followed by pelleting
and postfixation with 1% osmium tetroxide and embedding in epon-araldite
resin (Electron Microscopy Sciences). Thin sections were counterstained with
uranyl acetate and lead citrate.
Immunogold labeling for CD81 was done on unfixed, suspended
exosomes using 5 nm of colloidal gold conjugated to goat anti–mouse
IgG (GE Healthcare) followed by PFA fixation and adsorption and stain-
ing as described in the previous paragraph. Postembedding immunogold
labeling for MPMV p27CA was done on sections of lowicryl K4M–embed-
ded exosomes. Primary antibody bound to exosomes was detected with a
two-step protocol: incubation in rabbit anti–goat IgG (The Jackson Labora-
tory) followed by 5 nm of colloidal gold conjugated to goat anti–rabbit
IgG (GE Healthcare). Labeled thin sections were counterstained with ura-
nyl acetate. Negative control sections for immunogold labeling using irrel-
evant primary antibodies followed by detection steps showed an absence
of gold particles.
Image processing
Digital images of immunoblots were acquired by scanning the autoradio-
grams on a flatbed scanner, and digital images of plates with cell colonies
were acquired at RT with an inverted microscope (Axiovert 405M; Carl
Zeiss MicroImaging, Inc.) equipped with an Achroplan LD 20 lens, with
NA 0.4 (Carl Zeiss MicroImaging, Inc.), a Photometrics CH250 camera
(Roper Scientific), and OncorImage analysis software v. 2.0.5d. Immuno-
fluorescence images were acquired at RT using Axioskop 2 plus (Carl
Zeiss MicroImaging, Inc.) equipped with Plan Neo-Fluar 40 lens with
NA 0.75, AxioCam digital camera, and OpenLab 4.0.2 imaging soft-
ware. Images for figures were formatted using Adobe Photoshop, which
included change of contrast or brightness in some images, in which case
each image was processed as a whole. If contrast and brightness were
changed in multipanel images, the changes were performed on the entire
image. The figures were assembled using PowerPoint.
Online supplemental material
Table S1 shows the composition of exosomes, and Table S2 shows identi-
fication of viral peptides from fusogenic exosomes. Fig. S1 demonstrates
that the fusogen is infectious, and Fig. S2 gives evidence that productive
infection is not required for fusion and that normal cells fused by MPMV
survive but do not proliferate. Online supplemental material is available at
http://www.jcb.org/cgi/content/full/jcb.200507069/DC1.
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